GlaxoSmithKline

GSK and AnaptysBio are engaged in dueling lawsuits over their 11-year collaboration agreement covering the cancer immunotherapy Jemperli, with GSK seeking to terminate the deal and halve royalty payments.

GSK's subsidiary Tesaro has filed litigation in Delaware Chancery Court against AnaptysBio, alleging material breach of their 2014 license agreement for the cancer drug Jemperli (dostarlimab).

PolyModels Hub secured €7.9 million in Series A funding led by Molten Ventures to advance its ModelFlow platform for pharmaceutical process development.

ProFound Therapeutics and Quotient Therapeutics have signed the first feasibility agreements under Flagship Pioneering's framework collaboration with GSK to discover novel treatments for respiratory and liver diseases.

Pfizer's mRNA-based influenza vaccine demonstrated 34.5% greater effectiveness against influenza A compared to standard flu vaccines in a Phase 3 trial involving over 18,000 participants aged 18-64.

SCYNEXIS has completed the transfer of BREXAFEMME's New Drug Application to GSK, allowing the pharmaceutical giant to initiate FDA discussions for the antifungal drug's relaunch.

GSK and LTZ Therapeutics announced a strategic collaboration to develop up to four potential first-in-class myeloid cell engager therapies targeting hematologic cancers and solid tumors.

GSK and the Fleming Initiative announced six new research programs using advanced AI to tackle antimicrobial resistance, with £45 million in funding over three years starting in early 2026.

SCYNEXIS announced federal funding for a five-year, $7 million annual grant supporting development of next-generation triterpenoid antifungals (fungerps) to combat resistant fungal infections.

WRN inhibitors represent a fast-emerging precision oncology segment targeting DNA repair vulnerabilities in microsatellite instability-high (MSI-H) tumors through synthetic lethality mechanisms.